Synlogic (NASDAQ:SYBX) Announces Earnings Results, Beats Estimates By $0.04 EPS

Synlogic (NASDAQ:SYBX) announced its earnings results on Thursday. The biotechnology company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.04, Zacks reports.

Synlogic Price Performance

Shares of Synlogic stock opened at $1.32 on Friday. The business has a 50 day simple moving average of $1.39 and a two-hundred day simple moving average of $1.43. Synlogic has a 12 month low of $1.22 and a 12 month high of $2.04. The stock has a market capitalization of $15.44 million, a P/E ratio of -0.32 and a beta of 0.81.

Synlogic Company Profile

Synlogic, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.